Dr. Reddy’s Laboratories Ltd signed a definitive agreement with Haleon plc to purchase shares of Northstar Switzerland SARL, a company within the Haleon Group. The acquisition is valued at £500 million. The deal is anticipated to close in the early fourth quarter of this year. The integration of operations will occur in stages to ensure a smooth transition.
The acquisition includes the nicotine replacement therapy (NRT) portfolio of Nicotinell and its local brand variants, nicabate, habitrol, and thrive, in markets outside of the US.
As reported by businessline, Nicotinell has a presence in over thirty countries across Europe, Asia (including Japan), and Latin America. It is one of the top fifteen OTC brands in Europe (excluding Russia and Italy) and ranks 32nd among global OTC brands (excluding the US).
